Therapeutic
pipeline for analysis of psoriasis is likely to grow on account of increasing
prevalence of psoriasis, globally, which is caused due to abnormalities in the
immune system caused by external stressors and low market penetration of drugs
that can successfully cure the disease. According to the latest data published by
the American Academy of Dermatology, approximately 7.5 million people in the U.S.
are suffering from psoriasis. The disease is prevalent in people of all age
groups, mostly in adults. Both males and females are equally susceptible to
this disease.
Explore Report at: https://www.psmarketresearch.com/market-analysis/psoriasis-therapeutic-pipeline-analysis
Psoriasis is a
serious condition which includes chronic inflammation and scaling on the skin. Psoriasis
develops when skin cells rapidly grow below the surface of the skin and get
deposited on the surface before they get mature. Usually this process takes
about a month, but in psoriasis it may occur in a few days. Psoriasis leads to
the development of thick patches of inflamed skin with a silvery scale
covering. These patches are also referred to as plaques and they itch or feel
sore. They mostly occur on knees, elbows, other parts of the legs, lower back,
scalp, soles of the feet, face and palms. Psoriasis can also affect the
toenails, the fingernails, inside the mouth and the soft tissues of the
genitals. Pain and itching may interfere with basic functions such as
self-care, sleep and walking. Psoriasis is caused when T cells accidently get involved
and become active to the extent of triggering other immune responses, thus, resulting
in inflammation and rapid turnover of skin cells. Another major source of
developing psoriasis is its presence in the family history of an individual.
Psoriasis is diagnosed by examining a small skin sample from a patient, under a
microscope. There are several forms of psoriasis including guttate psoriasis, plaque
psoriasis, erythrodermic psoriasis, inverse psoriasis, pustular psoriasis and psoriatic
arthritis. The treatment of psoriasis includes topical treatment, phototherapy
and systemic therapy. Topical treatment includes application of ointment or
cream forms of corticosteroids, vitamin D3, retinoids, coal tar, or anthralin.
Phototherapy includes exposure of UV light in controlled conditions, while systemic
treatment includes retinoids, cyclosporine, methotrexate, PDE4 inhibitors and biologic
response modifiers medicines.
Some of the leading companies having a pipeline of psoriasis therapeutics include Novartis AG, UCB S.A., Pfizer, GlaxoSmithKline plc, Betta Pharmaceuticals Co., Ltd., AbbVie, Inc., Eli Lilly and Company, Santalis Pharmaceuticals, Inc., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Inc.
No comments:
Post a Comment